Abstract
Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Skeletal muscle wasting is a prominent feature of the disease and is believed to result from the loss of balance between protein synthesis and degradation. Quality of life and prognosis are severely compromised in patients with cancer cachexia. Despite current knowledge on the mediators involved in cancer cachexia, treatment targeting a single molecule has rendered limited effectiveness. This article aims to review the mediators of cancer cachexia and interventions attempted in the literature and discuss the common pathways leading to protein loss that these mediators modulate during cachexia. We believe that by targeting downstream effectors that are common in these pathways, a better therapeutic approach to reverse muscle wasting and maintain muscle function during cancer cachexia will be achieved.
Keywords: Cancer cachexia, mediators, metabolism, muscle wasting, signalling, transcription factors, RORα, Calcineurin, RNA-dependent, Protein, myotubes.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Cancer Cachexia: Molecular Targets and Pathways for Diagnosis and Drug Intervention
Volume: 12 Issue: 3
Author(s): Angie M.Y. Shum and Patsie Polly
Affiliation:
Keywords: Cancer cachexia, mediators, metabolism, muscle wasting, signalling, transcription factors, RORα, Calcineurin, RNA-dependent, Protein, myotubes.
Abstract: Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Skeletal muscle wasting is a prominent feature of the disease and is believed to result from the loss of balance between protein synthesis and degradation. Quality of life and prognosis are severely compromised in patients with cancer cachexia. Despite current knowledge on the mediators involved in cancer cachexia, treatment targeting a single molecule has rendered limited effectiveness. This article aims to review the mediators of cancer cachexia and interventions attempted in the literature and discuss the common pathways leading to protein loss that these mediators modulate during cachexia. We believe that by targeting downstream effectors that are common in these pathways, a better therapeutic approach to reverse muscle wasting and maintain muscle function during cancer cachexia will be achieved.
Export Options
About this article
Cite this article as:
M.Y. Shum Angie and Polly Patsie, Cancer Cachexia: Molecular Targets and Pathways for Diagnosis and Drug Intervention, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/187153012802002910
DOI https://dx.doi.org/10.2174/187153012802002910 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Current Diabetes Reviews Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Characteristics of Bax Inhibitor-1 and its Related Diseases
Current Molecular Medicine Role of Nanotechnology in Delivery of Protein and Peptide Drugs
Current Pharmaceutical Design Nitric Oxide Signaling and the Cross Talk with Prostanoids Pathways in Vascular System
Medicinal Chemistry New Imaging Tracers for the Infected Diabetic Foot (Nuclear and Optical Imaging)
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry The Effects of Antihypertensive Therapy on Haemostatic Parameters
Current Pharmaceutical Design Dipeptidyl Peptidase-4 Inhibitor Induced Angioedema – An Overlooked Adverse Drug Reaction?
Current Diabetes Reviews Epicardial Adipose Tissue: Another Tassel in the Complex Fabric of Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Targeting the SH2 Domain-Containing Inositol Phosphatase (SHIP) for Therapy
Current Enzyme Inhibition Nanosuspension: Principles, Perspectives and Practices
Current Drug Delivery The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Rapid Determination of Acarbose in Tablets by 1H NMR Spectroscopy
Current Pharmaceutical Analysis Recent Medicinal Chemistry Approach for the Development of Dipeptidyl Peptidase IV Inhibitors
Current Medicinal Chemistry Deciphering the Physiology Underlying the Rapid Clinical Effects of Perispinal Etanercept in Alzheimers Disease
Current Alzheimer Research Tissue Plasminogen Activator (tPA) and Matrix Metalloproteinases in the Pathogenesis of Stroke: Therapeutic Strategies
CNS & Neurological Disorders - Drug Targets The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Thyroid Hormones and their Metabolites: Biological Roles and Association with Non-Alcoholic Fatty Liver Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) TGF-β Signaling in Gastrointestinal Cancer Stem Cells
Current Cancer Therapy Reviews